English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/211443
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

AuthorsMuñoz-Guardiola, Pau; Casas, Josefina ; Megías-Roda, Elisabet; Solé, Sonia; Perez-Montoyo, Héctor; Yeste-Velasco, Marc; Erazo, Tatiana; Dièguez-Martínez, Nora; Espinosa-Gil, Sergio; Muñoz-Pinedo, Cristina; Yoldi, Guillermo; Abad, José Luis ; Segura, Miguel F.; Moran, Teresa; Romeo, Margarita; Bosch-Barrera, Joaquim; Oaknin, Ana; Alfón, Jose; Domènech, Carles; Fabriàs, Gemma ; Velasco, Guillermo; Lizcano, José M.
KeywordsAutophagy
Cancer
Dihydroceramide
Clinical trial
ER stress
UPR
Issue Date13-May-2020
PublisherTaylor & Francis
CitationAutophagy (2020)
AbstractABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase expression, resulting in the inhibition of the AKT-MTORC1 axis and macroautophagy/autophagy-mediated cancer cell death. However, the precise molecular determinants involved in the cytotoxic autophagy caused by ABTL0812 remained unclear. Using a wide range of biochemical and lipidomic analyses, we demonstrated that ABTL0812 increases cellular long-chain dihydroceramides by impairing DEGS1 (delta 4-desaturase, sphingolipid 1) activity, which resulted in sustained ER stress and activated unfolded protein response (UPR) via ATF4-DDIT3-TRIB3 that ultimately promotes cytotoxic autophagy in cancer cells. Accordingly, pharmacological manipulation to increase cellular dihydroceramides or incubation with exogenous dihydroceramides resulted in ER stress, UPR and autophagy-mediated cancer cell death. Importantly, we have optimized a method to quantify mRNAs in blood samples from patients enrolled in the ongoing clinical trial, who showed significant increased DDIT3 and TRIB3 mRNAs. This is the first time that UPR markers are reported to change in human blood in response to any drug treatment, supporting their use as pharmacodynamic biomarkers for compounds that activate ER stress in humans. Finally, we found that MTORC1 inhibition and dihydroceramide accumulation synergized to induce autophagy and cytotoxicity, phenocopying the effect of ABTL0812. Given the fact that ABTL0812 is under clinical development, our findings support the hypothesis that manipulation of dihydroceramide levels might represents a new therapeutic strategy to target cancer.
Publisher version (URL)https://doi.org/10.1080/15548627.2020.1761651
URIhttp://hdl.handle.net/10261/211443
DOI10.1080/15548627.2020.1761651
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
The anticancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by.pdf3,09 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.